The current standard of care for psychosis is a diagnostic interview, but what if it could be diagnosed before the first symptom emerged? Researchers at the Del Monte Institute for Neuroscience at the University of Rochester are pointing toward a potential biomarker in the brain that could lead to more timely interventions and personalized care.

A new therapy for brittle type 1 diabetes, the only treatment currently approved by the U.S. Food and Drug Administration, is available exclusively at UI Health in Chicago.